Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab perioperative therapy for resectable stage II-III non-small cell lung cancer
CTR20200932Phase 3Active
- Sponsor
- MedImmune
- Start
- Apr 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by MedImmune. Started Apr 2021; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200932.